GQ Healthcare Collaborates with BioMap to Co-Develop FIC/BIC ADC Therapeutics for Multiple Targets
Shots:
- GQ Healthcare & BioMap entered into a partnership that integrates GQ's enzymatic site-specific conjugation technologies (iLDC and iGDC) and linker-payload platform with BioMap's life science AI Foundation, incl. the Large Language Model xTrimo and AI protein generation platform AIGP
- The collaboration leverages GQ's expertise in ADC drug development, incl. conjugation preparation & drug evaluation, with BioMap's innovative target recommendation platform, antibody design capabilities, & AI-driven data analysis
- The patnership aims to enhance R&D efficiency, reduce development costs, and facilitate the creation of highly competitive and innovative ADC drugs to address global unmet clinical needs.
Ref: PR Newswire | Image: GQ Healthcare
Related News:- BioMap Collaborated with Sanofi to Co-Develop AI Modules to Advance Drug Discovery for Biotherapeutics Using BioMap’s AI Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
